Adherium Director Increases Indirect Stake via Interest-for-Equity Swap

Adherium Ltd. ( (AU:ADR) ) has shared an update.

Adherium Limited has disclosed a change in director George Baran’s interests, reflecting an increase in his indirect holding of fully paid ordinary shares through Trudell Medical Limited, in which he has a one-third beneficial interest. The additional 22,371,011 shares were issued in lieu of cash as payment for $111,855 in unpaid accrued interest on convertible notes, simplifying the company’s capital structure and modestly increasing the director’s equity alignment with shareholders.

Following this transaction, Baran’s indirect stake in Adherium has risen to more than 1.42 billion fully paid ordinary shares, while his direct holdings remain unchanged. The move converts interest liabilities into equity, which marginally strengthens Adherium’s balance sheet and underscores continued financial support from a key shareholder-linked entity without immediate cash outlay by the company.

The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.

More about Adherium Ltd.

Adherium Limited is a healthcare technology company focused on respiratory care. It develops and supplies devices and digital solutions that support the monitoring and management of conditions such as asthma and chronic obstructive pulmonary disease, working with partners and investors to expand its presence in the medical technology market.

Technical Sentiment Signal: Sell

Current Market Cap: A$10.75M

Find detailed analytics on ADR stock on TipRanks’ Stock Analysis page.